Arcutis Biotherapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Arcutis Biotherapeutics Inc ARQT.OQ reported a quarterly adjusted loss of 33 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -73 cents. The mean expectation of seven analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -46 cents to -36 cents per share.
Revenue rose 17.4% to $44.76 million from a year ago; analysts expected $37.62 million.
Arcutis Biotherapeutics Inc's reported EPS for the quarter was a loss of 33 cents.
The company reported a quarterly loss of $41.54 million.
Arcutis Biotherapeutics Inc shares had held steady so far this quarter and gained 187.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 9.5% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is 19.00
This summary was machine generated from LSEG data November 6 at 11:19 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.42 | -0.33 | Beat |
Jun. 30 2024 | -0.52 | -0.42 | Beat |
Mar. 31 2024 | -0.73 | -0.32 | Beat |
Dec. 31 2023 | -0.77 | -0.72 | Beat |
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
